Market's view on Verici Dx
Published on April 2024
- A stock watcher noted recent significant buys, suggesting these might indicate a market bottom.
- Observations were made on unusual trading patterns with similarities in trade numbers hinting at possible strategic moves.
- Discussion about a potential buy that followed a large sell, suggesting a clearing of placement which could lead to price movement.
- The opportunity for investors to utilise their new ISA allowance at current price levels was highlighted.
- Concerns were raised about significant selling towards the end of the tax year despite a well-supported funding round.
- The company’s development deal with Thermo Fisher was mentioned positively, providing financial inflows from milestones although concerns about the sales timeline and revenue generation were expressed.
- Doubts were cast on the company’s financial runway reaching into 2026 despite recent fundraising, due to the current cash burn rate.
- Management’s lack of shareholding raised concerns about their commitment to the company’s success.
- Optimism was expressed about the company’s potential as a leading investment in the pharmaceutical sector on AIM.
- Legal developments involving competitor companies in patent infringement cases highlighted the competitive landscape and the potential strategic value of the company’s unchallenged technology.